Longitude’s Healthy Returns Pave the Way for New FundLife sciences investor Longitude Capital, which backs drug developers and medical devices, raises $385M for second fundByVCJ Staff22 October 2012•2 mins readJavaScript is required to read this article. Please enable it in your browser and reload the page.Managers
